Oura Inc. (NASDAQ: OURA) closes above $50.00 per share on its Nasdaq debut day (30 September 2026)
Miss
✦ AI-generated prediction
Published on 29. September 2026
·
Predicted for 30. September 2026
·
Based on: Speculative
Oura Inc. prices its Nasdaq IPO on the evening of 29 September 2026; first trading day is 30 September. Price range: $40–44/share (~$2.2B total offering). Order book was ~4× oversubscribed at close of bookbuilding. Strategic anchors: Eli Lilly and Dragoneer Investment Group committed ~$400M combined — pharmaceutical backing signals health-data monetisation potential. At top-of-range pricing ($44): $50 target = +13.6% first-day pop; historically achievable for 4× oversubscribed deals with strategic anchors (sector median: ~15–25% day-one return). Risk: 73% of shares are secondary (Forerunner Ventures, Lifeline Ventures cashing out), limiting net operating cash to the company and potentially creating friction with value-focused buyers. Nasdaq 100 at 30,369 (28 Sept.) — bullish backdrop.
Data basis for this prediction
- Oura IPO ~4-fach überzeichnet; Eli Lilly + Dragoneer Anchor ~400 Mio. USD (OctagonAI, Yahoo Finance, 26. Sept 2026)
- IPO Preisspanne: 40–44 USD, Ersthandelstag 30. Sept 2026 (StockAnalysis, RenaissanceCapital)
- 73 % Sekundärangebot (Forerunner/Lifeline); Vollverwässerung ~15 Mrd. USD (TechCrunch, 21. Sept 2026)
- Nasdaq 100 Schlussstand 28. Sept 2026: 30.369 Pkt. (Investing.com)
Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.
Verdict: Miss
[Vorzeitig entschieden] Oura Inc. verschob seinen geplanten NASDAQ-IPO (Ticker: OURA) am 29. September 2026 auf unbestimmte Zeit – offiziell wegen 'Marktunsicherheiten' (Quelle: TechCrunch). Am 30. September 2026 findet kein Börsenhandel statt; ein Schlusskurs über 50 USD ist unmöglich.
💻 Technology
✦ AI
Applied Materials has beaten the EPS consensus in all four of its last reported quarters, with an average earnings surprise of +3.5%. The company's own Q4 guidance is $3.82–$4.22 per share; consensus at $4.06 sits near the midpoint, reflecting classic conservative management framing. Revenue is estimated at $10.30B (+51% YoY) — TSMC and Samsung have not pulled back H2 2026 capex plans. No Polymarket market directly available; a 100% beat streak over 4 quarters with a positive guidance range implies 70–75% probability. Risk: supply chain delays or expanded US export controls on advanced chips could force a Q5 inventory build.
💻 Technology
✦ AI
PLTR closed at $175.40 on November 4, 2026 (after-hours: $170.88, -2.58%; intraday high: $176.54; 52-week high: $212.94). Palantir clearly beat Q3-FY2026 EPS consensus: total revenue $2.313B, US Commercial revenue +148% YoY to $984M. The $185 threshold is +5.5% above the closing price or +8.3% above after-hours levels. Typical post-earnings 'sell the news' may weigh short-term, but the 52-week high of $212.94 confirms the level is reachable. NVIDIA earnings on November 18, 2026 could serve as a sector-wide catalyst. No direct Polymarket equivalent; own estimate: ~42%.
💻 Technology
✦ AI
CBRS trades at $109.18 (October 30, 2026) — already 61% below its all-time high of $279.72. The final and largest lockup expiration is scheduled for November 10, 2026: approximately 19.4 million shares are unlocked (of three tranches of 19.4M each). Prior lockup tranches have consistently weighed on the stock. Insiders have sold ~$394.6M in shares since the May 2026 IPO — zero insider purchases. A Culper Research short-seller report has triggered multiple investigations. A close below $100 requires a ~8.4% decline — plausible given the expected supply pressure on expiration day.